Freenome (NASDAQ:FRNM) Stock Has Consensus Price Target of $18.00 According to Brokerages

Shares of Freenome (NASDAQ:FRNM) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $18.00.

A number of analysts recently commented on the company. Guggenheim initiated coverage on Freenome in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price for the company. BTIG Research assumed coverage on Freenome in a report on Monday, August 17th. They issued a “buy” rating and a $17.00 price target on the stock. TD Cowen began coverage on Freenome in a report on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price target on the stock. Weiss Ratings started coverage on Freenome in a research note on Monday, August 24th. They issued a “sell (d+)” rating for the company. Finally, Leerink Partners assumed coverage on Freenome in a research note on Friday, August 14th. They issued an “outperform” rating and a $18.00 price objective for the company.

Freenome Stock Down 4.4%

FRNM stock opened at $12.64 on Wednesday. The company has a market cap of $1.36 billion, a PE ratio of -210.63 and a beta of 0.44. The stock’s 50-day moving average is $15.14. Freenome has a 1 year low of $9.97 and a 1 year high of $17.50.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at early stages. The company combines artificial intelligence, machine learning and multi-omic analysis of blood samples to identify biological signals associated with cancer, including signals from tumors and the immune system.

Freenome’s primary focus has been the development of noninvasive screening tests for colorectal cancer and other common cancers. Its platform is intended to support earlier detection through routine blood draws, with colorectal cancer screening among the company’s most advanced areas of development.